Chronic mechanistic target of rapamycin inhibition: Preventing cancer to delay aging, or vice versa?

Cancer and Aging: From Bench to Clinics

Volumn 38, Issue , 2013, Pages 1-16

  Sharp, Zelton Dave ^a   Curiel, Tyler Jay ^a   Livi, Carolina Becker ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; RAPAMYCIN; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE;

AGING; ANIMAL; CAENORHABDITIS ELEGANS; CALORIC RESTRICTION; DROSOPHILA MELANOGASTER; DRUG EFFECT; DRUG SCREENING; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIFE EXPECTANCY; METABOLISM; MOUSE; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; TIME; DRUG EFFECTS; NEOPLASMS;

AGING; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CAENORHABDITIS ELEGANS; CALORIC RESTRICTION; DROSOPHILA MELANOGASTER; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOSUPPRESSION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIFE EXPECTANCY; MICE; MULTIPROTEIN COMPLEXES; NEOPLASMS; SIGNAL TRANSDUCTION; SIROLIMUS; SYSTEMS BIOLOGY; TIME; TOR SERINE-THREONINE KINASES;

EID: 84890298583     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000343625     Document Type: Chapter

References (94)

1. Bonneux L, Barendregt JJ, Nusselder WJ, et al: Preventing fatal diseases increases healthcare costs:cause elimination life table approach. BMJ 1998;316:26-29.
2. Juckett DA: What determines age-related disease:do we know all the right questions? Age (Dordr) 2010;32:155-160.
3. Blagosklonny MV, Campisi J: Cancer and aging:more puzzles, more promises? Cell Cycle 2008;7:2615-2618.
4. Hursting SD, Lavigne JA, Berrigan D, et al: Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med 2003;54:131-152.
5. Weindruch R, Sohal RS: Seminars in medicine of the Beth Israel Deaconess Medical Center. Caloric intake and aging. N Engl J Med 1997;337:986-994.
6. Richardson A, Heydari AR, Morgan WW, et al: Use of transgenic mice in aging research. ILAR J 1997;38:125-136.
7. Ikeno Y, Bronson RT, Hubbard GB, et al: Delayed occurrence of fatal neoplastic diseases in Ames dwarf mice: correlation to extended longevity. J Gerontol A Biol Sci Med Sci 2003;58:291-296.
8. Ikeno Y, Hubbard GB, Lee S, et al: Reduced Incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J Gerontol A Biol Sci Med Sci 2009;64:522-229.
9. Miller RA: Geroncology: the study of aging as the study of cancer; in Esser K, Martin GM (eds):Molecular Aspects of Aging. Chichester, Wiley, 1995, pp 265-278.
10. Campisi J: Cancer and ageing: rival demons? Nat Rev Cancer 2003;3:339-349.
11. He W, Sengupta M, Velkoff V, et al: 65+ in the United States: 2005. Current Population Reports. Washington, US Government Printing Office, 2005.
12. Older Americans 2010: Key Indicators of Well-Being, Federal Interagency Forum on Aging-Related Statistics. Washington, US Government Printing Office, 2010.
13. Jemal A, Siegel R, Ward E, et al: Cancer Statistics. 2009. CA Cancer J Clin 2009;59:225-249.
14. Altekruse SF, Kosary CL, Krapcho M, et al: SEER Cancer Statistics Review 1975-2007. Bethesda, National Cancer Institute, 2010.
15. Pal SK, Katheria V, Hurria A: Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J Clin 2010;60:120-132.
16. Caron E, Ghosh S, Matsuoka Y, et al: A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010;6:453.
17. Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 2012;149:274-293.
18. Nadon NL, Strong R, Miller RA, et al: Design of aging intervention studies: the NIA interventions testing program. Age (Dordr) 2008;30:187-199.
19. Harrison DE, Strong R, Sharp ZD, et al: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392-395.
20. Miller RA, Harrison DE, Astle CM, et al: Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci 2011;66:191-201.
21. Sharp ZD: Aging and TOR: interwoven in the fabric of life. Cell Mol Life Sci 2011;68:587-597.
22. Powers RW 3rd, Kaeberlein M, Caldwell SD, et al: Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev 2006;20:174-184.
23. Hertweck M, Gobel C, Baumeister R: C. elegans SGK-1 is the critical component in the Akt/PKB kinase complex to control stress response and life span. Dev Cell 2004;6:577-588.
24. Vellai T, Takacs-Vellai K, Zhang Y, et al: Genetics:influence of TOR kinase on lifespan in C. elegans. Nature 2003;426:620.
25. Kapahi P, Zid BM, Harper T, et al: Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004;14:885-890.
26. Kaeberlein M: Lessons on longevity from budding yeast. Nature 200;464:513-519.
27. Sonenberg N: eIF4E, the mRNA cap-binding protein:from basic discovery to translational research. Biochem Cell Biol 2008;86:178-183.
28. Zid BM, Rogers AN, Katewa SD, et al: 4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell 2009;139:149-160.
29. Syntichaki P, Troulinaki K, Tavernarakis N: eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature 2007;445:922-926.
30. Sonenberg N, Hinnebusch AG: Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009;136:731-745.
31. Pan KZ, Palter JE, Rogers AN, et al: Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell 2007;6:111-119.
32. Hamilton B, Dong Y, Shindo M, et al: A systematic RNAi screen for longevity genes in C. elegans. Genes Dev 2005;19:1544-1555.
33. Hsieh CC, Papaconstantinou J: Akt/PKB and p38 MAPK signaling, translational initiation and longevity in Snell dwarf mouse livers. Mech Ageing Dev 2004;125:785-798.
34. Sharp ZD, Bartke A: Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J Gerontol A Biol Sci Med Sci 2005;60:293-300.
35. Selman C, Tullet JMA, Wieser D, et al: Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009;326:140-144.
36. Sharp ZD, Strong R: The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. J Gerontol A Biol Sci Med Sci 2010;65:580-589.
37. Yilmaz OH, Katajisto P, Lamming DW, et al: mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature 2012;486:490-495.
38. Troca-Marin JA, Alves-Sampaio A, Montesinos ML: Deregulated mTOR-mediated translation in intellectual disability. Prog Neurobiol 2012;96:268-282.
39. Halloran J, Hussong S, Burbank R, et al: Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. Neuroscience 2012;223:102-113.
40. Kalender A, Selvaraj A, Kim SY, et al: Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metab 2010;11:390-401.
41. Sharp Z, Richardson A: Aging and cancer: can mTOR inhibitors kill two birds with one drug? Target Oncol 2011;6:41-51.
42. Barbet NC, Schneider U, Helliwell SB, et al: TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell 1996;7:25-42.
43. Bjedov I, Toivonen JM, Kerr F, et al: mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 2010;11:35-46.
44. Hasty P: Rapamycin: the cure for all that ails. J Mol Cell Biol 2009;2:17-19.
45. Cantley LC: The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
46. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510.
47. Hsieh AC, Costa M, Zollo O, et al: Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010;17:249-261.
48. She Q-B, Halilovic E, Ye Q, et al: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010;18:39-51.
49. Hsieh A, Liu Y, Edlind M, et al: The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
50. Ingolia NT, Ghaemmaghami S, Newman JR, et al: Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling. Science 2009;324:218-223.
51. Bakan I, Laplante M: Connecting mTORC1 signaling to SREBP-1 activation. Curr Opin Lipidol 2012;23:226-234.
52. Laplante M, Sabatini DM: An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009;19:R1046-R1052.
53. Duvel K, Yecies JL, Menon S, et al: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010;39:171-183.
54. Zitvogel L, Tesniere A, Kroemer G: Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006;6:715-727.
55. Curiel TJ: Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241-246.
56. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-1570.
57. Dunn GP, Old LJ, Schreiber RD: The three E's of cancer immunoediting. Ann Rev Immunol 2004;22:329-360.
58. Koebel CM, Vermi W, Swann JB, et al: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907.
59. Stephens JK, Everson GT, Elliott CL, et al: Fatal transfer of malignant melanoma from multiorgan donor to four allograft recipients. Transplantation 2000;70:232-236.
60. Strauss DC, Thomas JM: Transmission of donor melanoma by organ transplantation. Lancet Oncol 2010;11:790-796.
61. Fulop T, Larbi A, Kotb R, et al: Aging, immunity, and cancer. Discov Med 2011;11:537-550.
62. Vallejo AN: Immunological hurdles of ageing:indispensable research of the human model. Ageing Res Rev 2011;10:315-318.
63. Haynes L, Eaton SM, Burns EM, et al: Inflammatory cytokines overcome age-related defects in CD4 T-cell responses in vivo. J Immunol 2004;172:5194-5199.
64. Hurez V, Daniel BJ, Sun L, et al: Mitigating agerelated immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 2012;72:2089-2099.
65. Rosenkranz D, Weyer S, Tolosa E, et al: Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J Neuroimmunol 2007;188:117-127.
66. Ruby CE, Weinberg AD: OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. J Immunol 2009;182:1481-1489.
67. Zhang H, Podojil JR, Luo X, et al: Intrinsic and induced regulation of the age-associated onset of spontaneous experimental autoimmune encephalomyelitis. J Immunol 2008;181:4638-4647.
68. Bansal-Pakala P, Croft M: Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 2002;169:5005-5009.
69. Lustgarten J, Dominguez AL, Thoman M: Aged mice develop protective antitumor immune responses with appropriate costimulation. J Immunol 2004;173:4510-4515.
70. Shi Y, August DA: A new trick for an old drug:mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence. Cancer Biol Ther 2008;7:397-398.
71. Araki K, Turner AP, Shaffer VO, et al: mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-112.
72. Delgoffe GM, Kole TP, Zheng Y, et al: The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009;30:832-844.
73. Haxhinasto S, Mathis D, Benoist C: The AKTmTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008;205:565-574.
74. Weichhart T, Costantino G, Poglitsch M, et al: The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29:565-577.
75. Weichhart T, Saemann MD: The multiple facets of mTOR in immunity. Trends Immunol 2009;30:218-226.
76. Vezys V, Yates A, Casey KA, et al: Memory CD8 T-cell compartment grows in size with immunological experience. Nature 2009;457:196-199.
77. Ferrer IR, Wagener ME, Robertson JM, et al: Cutting edge: rapamycin augments pathogen-specific but not graft-reactive CD8+ T cell responses. J Immunol 2010;185:2004-2008.
78. Vezina C, Kudelski A, Sehgal SN: Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-726.
79. Chaudhary SC, Kurundkar D, Elmets CA, et al: Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol 2012;88:1149-1156.
80. Peterson TR, Laplante M, Thoreen CC, et al: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009;137:873-886.
81. Khokhar NZ, Altman JK, Platanias LC: Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011;23:578-586.
82. Pal SK, Figlin RA: Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Target Oncol 2011;6:5-16.
83. Coppin C, Kollmannsberger C, Le L, et al: Targeted therapy for advanced renal cell cancer: a Cochrane systematic review of published randomised trials. BJU Int 2011;108:1556-1563.
84. Vishnu P, Mathew J, Tan WW: Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther 2011;4:97-113.
85. Burgio SL, Fabbri F, Seymour IJ, et al: Perspectives on mTOR inhibitors for castration-refractory prostate cancer. Current Cancer Drug Targets 2012, E-pub ahead of print.
86. O'Regan R, Hawk NN: mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 2011;15:859-872.
87. Argyriou P, Economopoulou P, Papageorgiou S: The role of mTOR Inhibitors for the treatment of B-cell lymphomas. Adv Hematol 2012;2012:435342.
88. Stanford MM, Shaban M, Barrett JW, et al: Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2008;16:52-59.
89. Lun XQ, Zhou H, Alain T, et al: Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007;67:8818-8827.
90. Perry J, Okamoto M, Guiou M, et al: Novel therapies in glioblastoma. Neurol Res Int 2012;2012:428565.
91. Mohankumar V, Dhanushkodi NR, Raju R: Sindbis virus replication, is insensitive to rapamycin and torin1, and suppresses Akt/mTOR pathway late during infection in HEK cells. Biochem Biophys Res Commun 2011;406:262-267.
92. Alain T, Lun X, Martineau Y, et al: Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 2010;107:1576-1581.
93. Demidenko ZN, Blagosklonny MV: Growth stimulation leads to cellular senescence when the cell cycle is blocked. Cell Cycle 2008;7:3355-3361.
94. Demidenko ZN, Zubova SG, Bukreeva EI, et al: Rapamycin decelerates cellular senescence. Cell Cycle 2009;8:1888-1895.